Diagnostic antibody kits are used to detect various infectious and chronic diseases. The high burden of infectious and chronic diseases globally, regulatory approvals of test kits containing antibodies, availability of funding for research using diagnostic antibodies, and the high number of unintended pregnancies and births leading to the demand for pregnancy test kits are the factors driving the growth of this market. The initiatives taken by public and private government organizations to increase diagnostic testing to eradicate infectious diseases and the growing prevalence of diseases in emerging countries are likely to offer significant growth opportunities for the growth of this market.
Meticulous Research®, in its latest publication on the Diagnostic Specialty Antibodies Market, states that this market will increase at a CAGR of 4.6% from 2022–2029 to reach $39.99 Billion by 2029.
Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5241
The global diagnostic specialty antibodies market is segmented based on Type (Primary Antibodies, Secondary Antibodies), Clonality (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies), Technique (Western Blot [WB], Lateral Flow Assay, Enzyme-Linked Immunosorbent Assay [ELISA], Immunohistochemistry [IHC], Immunoprecipitation [IP], Immunocytochemistry [ICC], Other Techniques), Conjugate (Conjugated, Unconjugated), Application (Infectious Diseases [Parasitic Infections: Dengue, Malaria, and Other Parasitic Infections], [Blood Borne Infections: Hepatitis, HIV, and Other Blood Borne Infections], [Gastrointestinal Infections: Salmonellosis, E. Coli Infections, and Other Gastrointestinal Infections], [Respiratory Infections: COVID-19, Tuberculosis, Pneumonia, Influenza, and Other Respiratory Infections], Oncology, Pregnancy Detection/Fertility Testing, and Other Applications), and Geography
Based on geography, North America is estimated to command the largest share of this market in 2022, followed by Europe. The major share of North America is mainly attributed to the growing prevalence of diseases, such as COVID-19, cancer, HIV, hepatitis; the increasing funding for diagnostic research activities; and the government initiatives for increasing COVID-19 testing.
However, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to the rising prevalence of diseases and the increasing incidences of unintended pregnancies in the region. In addition, the initiatives by public and private organizations to promote the use of COVID-19 antigen kits for diagnosis further contribute to market growth in the region.
Based on type, the market is segmented into primary antibodies and secondary antibodies. The primary antibodies segment is slated to register the faster CAGR during the forecast period. Primary antibodies are highly preferred over secondary antibodies as primary antibodies can directly bind to the targeted antigen and are requisite in every assay. In addition, the regulatory approvals of primary antibody-based kits further contribute to the market growth of this segment.
Based on clonality, the market is segmented into monoclonal, polyclonal, and recombinant. The recombinant segment is expected to grow at the fastest rate by 2029. Recombinant antibodies are more cost-effective than monoclonal antibodies and have a better affinity for binding to the target antigen. In addition, recombinant monoclonal antibodies are produced in a shorter duration and have higher reproducibility over other clonal antibodies. These factors contribute to its demand in the market.
Based on technique, the market is segmented into western blot, ELISA, lateral flow assay, immunohistochemistry, immunoprecipitation, immunocytochemistry, and others. The lateral flow assay segment is expected to grow at the highest CAGR during the forecast period. Various organizations are promoting the usage of lateral flow assays to improve the diagnosis rate of various diseases, such as HIV and COVID-19 infections. In addition, lateral flow assays are less expensive and provide faster results than other techniques, such as western blot and IHC.
Based on conjugate, the market is segmented into conjugated antibodies and unconjugated antibodies. The unconjugated antibodies segment is estimated to account for the larger share of the market in 2022. The high affinity and sensitivity of unconjugated antibodies in assays are the key factors contributing to the demand for unconjugated antibodies in the market. In addition, the capability of an unconjugated antibody to form secondary antibody conjugates further drives its demand in the market.
Based on application, the market is segmented into infectious diseases, oncology, blood group typing, pregnancy detection/fertility testing, and others. The oncology segment is estimated to witness the fastest CAGR during the forecast period. The significant burden of cancer globally, initiatives by several public organizations to improve cancer diagnosis, and product approvals of antibody-containing cancer test kits are the prime factors contributing to the growth of this segment.
The report provides competitive intelligence in terms of financials, growth strategies, product portfolios, and geographical presence on some of the key players operating in the global Diagnostic Specialty Antibodies Market are Abcam plc (U.K.), F. Hoffman La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Rockland Immunochemicals, Inc. (U.S.), Santa Cruz Biotechnology (U.S.), Novus Biologicals, LLC (U.S.), and Thermo Fisher Scientific Inc. (U.S.).
To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/diagnostic-specialty-antibodies-market-5241
Author:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research